A Phase I Study of Bevacizumab (B) in Combination with Everolimus (E) and Erlotinib (E) in Advanced Cancer (BEE)

PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus and erlotinib combination. METHODS: Doublet therapy consisted of...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bullock, Karen E., Petros, William P., Younis, Islam, Uronis, Hope E., Morse, Michael A., Blobe, Gerard C., Zafar, S. Yousuf, Gockerman, Jon P., Lager, Joanne J., Truax, Roxanne, Meadows, Kellen L., Howard, Leigh A., O’Neill, Margot M., Broadwater, Gloria, Hurwitz, Herbert I., Bendell, Johanna C.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086252/
https://ncbi.nlm.nih.gov/pubmed/21079958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1507-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky